Artiva Biotherapeutics (ARTV) Payables (2023 - 2026)

Artiva Biotherapeutics (ARTV) has reported Payables for 4 consecutive years, with $2.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Payables rose 12.28% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $2.3 million (up 12.28% YoY), while the FY2025 annual figure was $355000.0, down 68.33% from the prior year.
• Payables grew to $2.3 million in Q1 2026 per ARTV's latest filing, from $355000.0 in the prior quarter.
• Across five years, Payables topped out at $2.3 million in Q1 2026 and bottomed at $355000.0 in Q4 2025.
• Historically, Payables has averaged $1.2 million across 4 years, with a median of $1.1 million in 2024.
• Annual changes were most pronounced in 2024 — Payables jumped 82.57% — and 2025, when it tumbled 68.33%.
• Artiva Biotherapeutics' Payables stood at $614000.0 in 2023, then jumped by 82.57% to $1.1 million in 2024, then sank by 68.33% to $355000.0 in 2025, then surged by 543.94% to $2.3 million in 2026.
• Business Quant data shows ARTV's Payables at $2.3 million in Q1 2026, $355000.0 in Q4 2025, and $848000.0 in Q3 2025.